Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $2,286,779.95 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $46.45, for a total transaction of $2,286,779.95. Following the transaction, the insider now owns 6,926 shares in the company, valued at approximately $321,712.70. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Monday, September 30th, Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.24, for a total value of $44,297.92.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The shares were sold at an average price of $47.00, for a total value of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06.

Janux Therapeutics Stock Down 1.8 %

JANX stock opened at $45.43 on Tuesday. The stock has a market capitalization of $2.36 billion, a P/E ratio of -37.24 and a beta of 3.57. Janux Therapeutics, Inc. has a 52 week low of $5.65 and a 52 week high of $65.60. The firm has a 50-day simple moving average of $43.87 and a 200-day simple moving average of $44.64.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. The business had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The company’s revenue was up 709.1% compared to the same quarter last year. On average, analysts expect that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Scotiabank decreased their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Stifel Nicolaus assumed coverage on Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research note on Monday, August 19th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $66.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JANX. Logos Global Management LP grew its holdings in shares of Janux Therapeutics by 400.0% during the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after buying an additional 600,000 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in Janux Therapeutics during the first quarter worth about $20,420,000. Vanguard Group Inc. grew its stake in Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares in the last quarter. Altitude Crest Partners Inc. acquired a new stake in Janux Therapeutics in the 1st quarter valued at about $7,278,000. Finally, Point72 Asset Management L.P. purchased a new position in Janux Therapeutics in the 2nd quarter worth approximately $5,715,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.